Publication of MBL DIP Supplement
Summary by AI BETAClose X
Announcement
Publication of Prospectus Supplement
The following prospectus supplement (the Supplement) has been approved by the Financial Conduct Authority and is available for viewing:
Macquarie Bank Limited (MBL) Supplement dated 7 November 2025 to the USD 25,000,000,000 MBL Debt Instrument Programme prospectus dated 6 June 2025 (the Prospectus)
To view the full document, please paste the following URL into the address bar of your browser.
http://www.rns-pdf.londonstockexchange.com/rns/6853G_1-2025-11-7.pdf
In addition, MBL has published a copy of the MBL Interim Financial Report for the half year ended 30 September 2025 (the Interim Report) on the Macquarie website at http://www.macquarie.com
To view the full document, please paste the following URL into the address bar of your browser:
https://www.macquarie.com/assets/macq/investor/reports/2026/macquarie-bank-hy26-interim-report.pdf
A copy of each of the Supplement and the Interim Report has also been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism
For further information, please contact:
Macquarie Bank Limited
Mr. Francisco Sarmiento
Level 1, 1 Elizabeth Street
Sydney NSW 2000
Australia
Telephone : +61 2 8232 3333
Fax : +61 2 8232 4227
Email: Francisco.Sarmiento@macquarie.com
DISCLAIMER ‑ INTENDED ADDRESSEES
Please note that the information contained in the Supplement may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Prospectus, as supplemented, is not addressed. Prior to relying on the information contained in the Prospectus, as supplemented, you must ascertain from the Prospectus, as supplemented, whether or not you are part of the intended addressees of the information contained therein.
Your right to access this service is conditional upon complying with the above requirement.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 7 hours ago Luceco
- 7 hours ago Helios Towers
- 8 hours ago Wise Class A
- 8 hours ago EDX Medical Group Plc
- 8 hours ago Naked Wines